ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Holdings Decreased by American Century Companies Inc.

American Century Companies Inc. decreased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 10.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,773,562 shares of the biotechnology company’s stock after selling 436,091 shares during the period. American Century Companies Inc. owned about 1.60% of ADMA Biologics worth $64,717,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of ADMA. Larson Financial Group LLC acquired a new stake in ADMA Biologics during the third quarter valued at approximately $31,000. GAMMA Investing LLC raised its position in shares of ADMA Biologics by 106.6% during the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 967 shares in the last quarter. National Bank of Canada FI bought a new position in ADMA Biologics during the third quarter worth $35,000. Vision Financial Markets LLC bought a new position in shares of ADMA Biologics in the 4th quarter worth about $51,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of ADMA Biologics in the 3rd quarter worth about $62,000. Institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Price Performance

NASDAQ ADMA opened at $20.22 on Wednesday. ADMA Biologics, Inc. has a 52 week low of $5.90 and a 52 week high of $23.64. The stock has a market cap of $4.78 billion, a price-to-earnings ratio of 72.21 and a beta of 0.60. The company has a 50-day moving average price of $16.91 and a two-hundred day moving average price of $18.10. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.